ACRV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Acrivon Therapeutics Inc (ACRV) is not a strong buy at this moment for a beginner investor with a long-term strategy. Despite recent price increases, the company shows weak financial performance, no significant trading trends, and lacks positive news or catalysts. It is better to monitor the stock for further developments before making an investment decision.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 76.485, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading above its pivot point of 1.644 but remains below key resistance levels (R1: 1.786, R2: 1.873). Overall, the technical indicators suggest mixed signals with no clear entry point.
The stock price has shown a significant increase in the regular market (9.52%) and pre-market (4.17%). Piper Sandler raised the price target to $8 from $6, citing promising Phase II data and future IND submission plans for a new inhibitor.
The company's financials are weak, with no revenue growth, a significant net income loss (-18.75% YoY), and declining EPS (-20.34% YoY). There are no significant trading trends from hedge funds or insiders, and no recent news or congress trading data is available.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$18.23 million (-18.75% YoY), and a decline in EPS to -0.47 (-20.34% YoY). Gross margin remains at 0%. Overall, the financial performance is poor.
Piper Sandler maintains an Overweight rating and raised the price target to $8 from $6, citing positive Phase II data and future development plans. However, no other analyst updates are available.
